Pharmaceutical combination containing Mosapride citrate

A technology for mosapride citrate and dispersible tablets, which is applied in the direction of medical preparations containing active ingredients, organic active ingredients, pill delivery, etc., can solve the problems of low solubility, instability of mosapride citrate, and production problems. High cost and other issues, to achieve the effect of stable quality
CN101273973BActive Publication Date: 2010-04-07CHENGDU KANGHONG PHARMA GRP
5 Cites 16 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
CHENGDU KANGHONG PHARMA GRP
Publication Date
2010-04-07

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to a pharmaceutical composition containing mosapride citrate which is applicable to the usage of direct powder compression for preparation and a preparation method thereof. The pharmaceutical composition further contains a disintegrant, a thinner, a lubricant, a glidant and an adhesive in addition to the active component of the mosapride citrate. The pharmaceutical composition is applicable to the preparation of dispersible tablets which can be fully disintegrated in 2 minutes in water under the temperature of 19 DEG C to 21 DEG C and pass through a No. 2 screen, the hardness is 8 to 11Kg, and the dissolution rate is in line with the relevant provisions, thus solving the problems of higher relevant substances, instable quality and difficult packaging of the mosapridecitrate dispersible tablets prepared by wet granulation.
Need to check novelty before this filing date? Find Prior Art

Description

field of invention

[0001] The invention relates to the field of pharmaceutical preparations, in particular to a dispersible tablet containing mosapride citrate. Background technique

[0002] Mosapride citrate, namely (±)-4-amino-5-chloro-2-ethoxy-N-{[4-(4-fluorobenzyl)-2-morpholine]methyl}benzene Formamide citrate dihydrate is a third-generation gastric motility drug developed by Dainippon Pharmaceutical Co., Ltd., see, for example, Japanese patent JP3090274, European patent EP0243959, and US patent US4870074. Mosapride citrate is a new type of gastric motility drug, a potent and selective 5-HT4 receptor agonist, which increases the release of acetylcholine from nerve endings, thereby promoting gastric emptying [Katayama K, Morio Y, Haga K, et al . cisapride. a gastroprokinetic agent, binds to 5-HT4 receptors [J]. Nippon Yakurigaku Zasshi, 1995, 105(6): 461-468.]. It is clinically used for the relief of a series of gastrointestinal symptoms associated with chronic gastriti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More